MRK keytruda® (pembrolizumab) as monotherapy significantly improved progression-free survival (pfs) in certain patients with advanced or rec

MRK keytruda® (pembrolizumab) as monotherapy significantly improved progression-free survival (pfs) in certain patients with advanced or recurrent endometrial cancer with mismatch repair deficient (dmmr) tumors compared to chemotherapy Merck & Co - phase 3 keynote-c93 trial meets primary endpoint of progression-free survival - Interim analysis shows trend toward improved os for Keytruda; os data not mature - Keytruda safety profile consistent with previous studies; no new safety signals identified